Tag Archives: Kevin Degeeter

Analysts Are Bullish on These Healthcare Stocks: Vericel (VCEL), Immunomedics (IMMU)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vericel (VCEL – Research Report) and Immunomedics (IMMU – Research Report) with bullish sentiments. Vericel (VCEL) Oppenheimer analyst Kevin DeGeeter maintained a

Cidara Therapeutics (CDTX) Received its Third Buy in a Row

After Needham and Wedbush gave Cidara Therapeutics (NASDAQ: CDTX) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Kevin DeGeeter maintained a Buy rating on Cidara Therapeutics today and set a price target of

Oppenheimer Maintains Their Buy Rating on Personalis (PSNL)

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Personalis (PSNL – Research Report) yesterday and set a price target of $24.00. The company’s shares closed last Monday at $7.00, close to its 52-week low of $4.27. According to TipRanks.com,

Moleculin Biotech (MBRX) Receives a Buy from Oppenheimer

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Moleculin Biotech (MBRX – Research Report) today and set a price target of $2.00. The company’s shares closed last Monday at $0.65, close to its 52-week low of $0.32. According to

Oppenheimer Keeps Their Buy Rating on Exact Sciences (EXAS)

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Exact Sciences (EXAS – Research Report) today. The company’s shares closed last Monday at $37.90, close to its 52-week low of $35.25. According to TipRanks.com, DeGeeter is a 1-star analyst with

Oppenheimer Maintains a Buy Rating on Molecular Templates (MTEM)

In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Molecular Templates (MTEM – Research Report). The company’s shares closed last Monday at $11.37. According to TipRanks.com, DeGeeter is currently ranked with no stars on a